HiTE webinar

​https://us06web.zoom.us/j/87844787820

Struggling with low transduction efficiency, high vector costs, or complex workflows? Join us for a live introduction to HiTE™ (High-Efficiency Transduction Enhancer) — a first-in-class Transient Fusion-Promoting Peptide (TFP) technology that is redefining what's possible in lentiviral transduction.

​What we'll cover:

​How HiTE™ works — a bi-functional synthetic peptide that binds both lentiviral envelope proteins and target cell membranes, promoting virus-cell proximity and membrane fusion, then self-inactivates within hours to preserve cell health.

​Head-to-head performance data across three clinically relevant cell types: → 63.0% transduction in primary CD3+ T cells (vs. 15.3% LentiBOOST, 8.0% Polybrene) → 73.9% in iPSCs (vs. 23.7% LentiBOOST, 16.8% Polybrene) → 33.3% in NK cells (vs. 0.7% LentiBOOST, 6.0% Polybrene)

​Safety and quality — >90% cell viability, VCN of 2.8 ± 0.1 (below FDA safety threshold), and a self-inactivating mechanism that eliminates lingering membrane disruption.

​Workflow simplification — no spinoculation, no plate coating, less than 8 hours from start to finish, and compatible with closed-system GMP manufacturing.

​Cost impact — 5–10× reduction in viral vector usage, potentially saving $25K–$250K per manufacturing batch.

​Live Q&A with our speaker

​Alyssa Carlson, Scientist II at Pyrojas and an expert in CRISPR/Cas9, cell engineering, and gene editing, will present the data and answer all your questions live.

​Who should attend: — Cell & gene therapy scientists — Process development engineers — CAR-T, CAR-NK, and iPSC researchers — CDMO and GMP manufacturing teams — Anyone working with lentiviral transduction

​Details: 📅 Friday, April 3, 2026 🕐 1:00 PM ET | 11:00 AM MT | 10:00 AM PT 💻 Virtual (link provided upon registration) 🎟️ Free

​Learn more at www.hitebio.com